Investigational drug · Phase 3
Brigimadlin
Also called: BI 907828
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumours, Pancreatic Neoplasms, Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
11
Any phase or sponsor naming "Brigimadlin"
First trial start
2022
Dec 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Brigimadlin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumours
- Pancreatic Neoplasms
- Solid Tumors
- Biliary Tract Cancer
- Lung Neoplasms
- Bladder Cancer
- Liposarcoma, Dedifferentiated
Approved drugs for the same conditions: Pancreatic cancer · Bladder and urothelial cancer · Sarcoma · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Brigimadlin" as an intervention, largest first.
- Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated LiposarcomaPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05218499 · 400 participants · Start Mar 31, 2022 · Primary completion Apr 16, 2024
Drug: Brigimadlin; Doxorubicin · For: Liposarcoma, Dedifferentiated
Sites: Birmingham, Alabama; Tucson, Arizona; Beverly Hills, California · 109 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03449381 · 266 participants · Start Jun 20, 2018 · Primary completion Nov 13, 2025
Drug: BI 907828 · For: Neoplasms
Sites: Santa Monica, California; New Haven, Connecticut; Sarasota, Florida · 27 sites in all
- Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated LiposarcomaPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06058793 · 138 participants · Start Dec 13, 2023 · Primary completion Dec 12, 2025
Drug: Brigimadlin · For: Liposarcoma, Dedifferentiated
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 56 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03964233 · 119 participants · Start Jun 20, 2019 · Primary completion Sep 5, 2024
Drug: BI 907828; ezabenlimab and 1 more · For: Neoplasms
Sites: Santa Monica, California; New Haven, Connecticut; Athens, Georgia · 23 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05512377 · 99 participants · Start Dec 13, 2022 · Primary completion Sep 25, 2025
Drug: Brigimadlin · For: Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer and 2 more
Sites: Mobile, Alabama; Tucson, Arizona; Los Angeles, California · 60 sites in all
- A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This MedicineActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06619509 · 90 participants · Start Dec 30, 2024 · Primary completion Dec 30, 2030
Drug: Brigimadlin · For: Solid Tumours
Sites: Beverly Hills, California; Santa Monica, California; New Haven, Connecticut · 50 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05372367 · 33 participants · Start Aug 11, 2022 · Primary completion Jul 17, 2024
Drug: BI 907828; Rifampicin and 1 more · For: Solid Tumors
Sites: Brussels, Belgium; Wilrijk, Belgium; Barcelona, Spain · 7 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05376800 · 24 participants · Start Nov 30, 2022 · Primary completion Jul 31, 2025
Drug: BI 907828 (Brigimadlin) · For: Glioblastoma
Sites: Phoenix, Arizona; New Haven, Connecticut; Jacksonville, Florida · 7 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05613036 · 13 participants · Start Jan 3, 2023 · Primary completion Apr 25, 2024
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1); [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2) and 1 more · For: Solid Tumors
Sites: Budapest, Hungary
- Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaPivotal-lookingWithdrawn
Boehringer IngelheimBoehringer Ingelheim
NCT06370871 · 0 participants · Start Jun 27, 2024 · Primary completion Jul 3, 2026
Drug: Brigimadlin; Ezabenlimab and 2 more · For: Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS)
Newest research
PubMed records naming it or its code names, newest first.
- Brightline-1: When a Negative Trial Reveals Two Active Therapies.
Shahnam A, Gounder MM · Clin Cancer Res 2026
- Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.
Schöffski P, Sanfilippo R, Martín-Broto J, et al. · Clin Cancer Res 2026
- MDM2-GPX4-ferroptosis regulatory axis exerts neurotoxic effects in intracerebral hemorrhage.
Yu Y, Liu T, Cai Y, et al. · Neural Regen Res 2026
- Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts.
Vaubel RA, Zhang W, Karbhari N, et al. · Neurooncol Adv 2026
- The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors.
Zhang W, Grams MP, Oberoi RK, et al. · Neuro Oncol 2025
- Real-World Experience Using Brigimadlin (MDM2 Inhibitor) in an Australian Sarcoma Specialist Center Compared to Pivotal Clinical Trial Results.
Gupta K, Grimison P · Asia Pac J Clin Oncol 2025
Also in development for Solid Tumours
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- ODM-212Phase 22 trials
Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer
- AZD4956Phase 21 trial
AstraZeneca · Solid Tumours
- BMS-986517Phase 21 trial
Bristol Myers Squibb · Solid Tumours
- EP0089-101Phase 21 trial
Ellipses Pharma · Solid Cancers, Solid Tumours
- GSK5864399Phase 21 trial
GSK · Solid Tumours
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.